Universiteit Antwerpen

Other

Katholieke Universiteit Leuven, Ku Leuven R&d

Yun Nv

K.u. Leuven Research & Development

Sarah Lebeer

Ingmar Claes

Camille Allonsius

Eline Oerlemans

Marianne Van Den Broek

Stijn Wittouck

Sander Wuyts

Peter Hellings

Ilke De Boeck

Tom Eilers

Tim Henkens

Filip Kiekens

The present invention generally relates to the use of a bifunctional peptidoglycan/chitin hydrolase to reduce and/or prevent hyphae formation in a pathogen, and/or to reduce or prevent biofilm formation. The present invention further relates to a bifunctional peptidoglycan/chitin hydrolase for use in the treatment and/or prevention of pathogenic infections, in particular yeast or bacterial infections. In another aspect, the present invention provides the use of a bifunctional peptidoglycan/chitin hydrolase as a anti-pathogenic agent in non-medical applications; in particular in the personal hygiene industry, food industry, cleaning industry, pharma industry, or biocontrol and crop protection industry.

Anti-pathogenic activity of a bifunctional peptidoglycan/chitin hydrolase

The present invention in particular relates to the identification of novelstrains which are characterized in having a whole genome GC content of less than 43%. Moreover, these strains are characterized by the expression of a novel cellulase enzyme, which has numerous applications in the fields of for example agriculture, bioconversion, detergents, fermentation, food, paper industry, or textile industry.

strains and cellulase derived therefrom

Aerosol sprays are provided that include one or more bacterial species and at least one siloxane suitable for applying said one or more bacterial species to a surface or into the environment. Such sprays may also include a propellant under pressure. Such aerosol sprays may be used for restoring or maintaining a healthy skin microbiota.

Aerosol spray containing viable bacterial species

The present invention is directed to a novel isolated bacterial strain of the() species. More in particular, the strain of thespecies deposited under accession number LMG P-30039. The present invention further relates to the novelstrain for use in the treatment and/or prevention of infections and/or immune-related diseases. Also the use of the isolated novelstrain or a composition comprising said strain as an adjuvant to promote an immune response during vaccination is disclosed. Further, the use of said novelstrain or a composition comprising said strain in personal hygiene industry, cleaning industry, biomass production, air purification and food industry is disclosed. In another aspect of the present invention, the use of aspecies that has a whole genome G/C content of at least 47.5% and expresses one or more catalase genes or a composition comprising one or more of saidspecies in personal hygiene industry, cleaning industry, biomass production, air purification and food industry is disclosed.

Probioticstrain and its uses

The present invention is directed to the direct application of beneficial or probiotic bacteria to the vaginal niche for maintenance of a healthy vaginal microbiota and to help restore an unbalanced vaginal microbiota. The application is based on the use of selectedstrains as anti-pathogenic agents, in particularand/or, against common vaginal pathogens, whereby produced acids such as lactic acid are important antimicrobial factors.

Vaginal preparations for maintaining and/or restoring healthy female microbiota

Growing community of inventors

Antwerp, Belgium

Sarah Lebeer